Cartesian Therapeutics (RNAC) Change in Accured Expenses (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Change in Accured Expenses for 12 consecutive years, with -$850000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 60.97% year-over-year to -$850000.0; the TTM figure through Mar 2026 stood at -$2.3 million (up 9.35% YoY), while the FY2025 annual figure was -$3.6 million, up 46.77% from the prior year.
• Change in Accured Expenses slipped to -$850000.0 in Q1 2026 per RNAC's latest filing, from $1.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.2 million in Q2 2022 and bottomed at -$6.4 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$689882.4 across 5 years, with a median of -$432000.0 in 2025.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 716.67% — and 2024, when it plunged 222.78%.
• Cartesian Therapeutics' Change in Accured Expenses stood at $1.6 million in 2022, then plunged by 171.21% to -$1.1 million in 2023, then soared by 203.56% to $1.2 million in 2024, then slipped by 8.94% to $1.1 million in 2025, then sank by 180.26% to -$850000.0 in 2026.
• Business Quant data shows RNAC's Change in Accured Expenses at -$850000.0 in Q1 2026, $1.1 million in Q4 2025, and -$432000.0 in Q3 2025.